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This review covers the development of the genusMicromonospora as a model for natural product research
and the timeline of discovery progress from the classical bioassay-guided approaches through the
application of genome mining and genetic engineering techniques that target specific products. It
focuses on the reported chemical structures along with their biological activities and the synthetic and
biosynthetic studies they have inspired. This survey summarizes the extraordinary biosynthetic diversity
that can emerge from a widely distributed actinomycete genus and supports future efforts to explore
under-explored species in the search for novel natural products.1. Introduction
Microbial natural products are considered an essential
component of today's drug arsenal. They revolutionized medi-
cine in the 20th century not just by treating mortal diseases, but
also by enabling life-saving procedures such as heart trans-
plantation or catheterization to be performed.1 The interest in
this historical drug resource is decreasing due to the continued
rediscovery of known metabolites. However, urgent demand for
new drug leads to combat antibiotic-resistant pathogenic
infections and other life-threatening diseases, together with the
low returns from alternative discovery platforms, has led to theharmacy, Cairo University, Cairo, Egypt,
Pharmacy, Nahda University, Beni-Suef,
harmacy, Beni-Suef University, Beni-Suef,
ysical Sciences, University of the West of
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ZIF), Partner Site Tübingen, Tübingen,
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tion (ESI) available. See DOI:
f Chemistry 2020revival of natural product research, especially from microbial
sources.2
Actinobacteria represent one of the largest bacterial phyla
which widespread across all natural habitats and clearly rep-
resented in both terrestrial and marine ecosystems3,4 as well as
extreme environments.5 Approximately 70% of the naturally-
derived compounds that are currently in the market or under
clinical trials are derived from them.6,7 The genus Micro-
monospora, a member of family Micromonosporaceae was origi-
nally proposed by Ørskov in 1923. Members of this genus are
Gram-positive, spore-forming aerobic Actinobacteria that own
unique morphological characteristics such as single spore
attached to short substrate hyphae. Also, they possess carot-
enoid mycelial pigments that showing yellow, orange, red,
purple, brown or black colonies.8 Species belonging to this
genus are widespread across diverse geographical habitats viz;
soil, mangrove sediment, marine sediment, plants, and extreme
habitats (e.g. hyper-arid deserts, deep-sea sediments and
hypersaline lakes) (Fig. 1 and 2).9 To date, this genus comprised
88 genuinely named species (http://www.bacterio.net) with
about 83% of them are of terrestrial origin including plants
endophytes and extreme habitats-derived-strains. On the other
hand, the marine-derived species are frequently reported from
both marine sediment and sponges (Fig. 2). A phylogenomic
tree (Fig. 3) of all Micromonospora genomes available at EzBio-
Cloud was calculated using bcgTree and 1000 bootstrap repli-
cates. Based on amino-acid sequences of whole-genome data,
this algorithm identied 107 crucial single-copy genes and
performs a partitioned maximum-likelihood analysis with
RaxML. The phylogenomic tree revealed that the genus Micro-
monospora inhabits a wide range of habitats, with environ-
mental origin not associated with monophyletic clades. ThisRSC Adv., 2020, 10, 20939–20959 | 20939
Fig. 1 Global locations from which the genus Micromonospora has been reported.
Fig. 2 (A) Percentage distribution of Micromonospora species by habitats. (B) M. rifamycinica,14 the main producer of rifamycin antibiotic (177),
and it always reported frommarine habitats. (C)M. echinospora,15 the main producer of gentamicin antibiotics (85–87). (D)M. rosaria,15 the main
producer of rosamicin antibiotic (7).
20940 | RSC Adv., 2020, 10, 20939–20959 This journal is © The Royal Society of Chemistry 2020
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View Article Online
Fig. 3 Phylogenomic tree of allMicromonospora genomes available at EzBioCloud with Actinoplanes as the outgroup. The tree was calculated
using bcgTree. Node bubbles represent maximum likelihood bootstrap support values with 1000 replicates. The colors of names are repre-
sentative for environmental origin of the isolate associated with the genome, with marine: blue, freshwater: purple, brown: soil, animal (feces):
red, plant associated (mostly roots): green and black: origin unknown.
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View Article Onlineindicates broad adaptability of the whole genus to inhabit
a variety of environments.
Micromonospora has been regarded as a reservoir of antimi-
crobial agents and other bioactive metabolites10 withThis journal is © The Royal Society of Chemistry 2020a biosynthetic potential comparable to the genus Streptomyces.11
There are two previous reviews that briey discussed the anti-
bacterial metabolites produced by members of this genus.12,13RSC Adv., 2020, 10, 20939–20959 | 20941
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View Article OnlineThemain aim of this review is to emphasize the development
of the Micromonospora genus as a model for microbial natural
product research, focusing on the discovery of its novel natural
products along with their important biological activities in
a chronological manner. Many uncommon Micromonospora-
derived metabolites that have inspired synthetic, biosynthetic,
and mechanistic scientists are highlighted. Early discovery
efforts utilized the traditional bioassay-guided approaches
while some of the recent reports result from the application of
genetic engineering and metabolomics approaches. Addition-
ally, this review summarizes the biosynthetic capacities of
Micromonospora illustrating how microbial natural products is
coupled with biological and biochemical investigations in an
interdisciplinary manner for the discovery of new natural drug
leads.2. Micromonospora: a promising
genus to mine for secondary
metabolites
To evaluate the potential of the genus Micromonospora to
produce secondary metabolites, we used a combination of
bioinformatics tools for analyzing the distribution of the rela-
tionships between biosynthetic gene clusters (BGCs).
autoMLST, a tool for phylogenomic classication of bacterial
genomes, contains a database of bacterial genomes and their
biosynthetic potential that is precalculated from antiSMASH
results.16,17 Using M. noduli GUI 43 as a query sequence,
a phylogenetic tree was generated from 50 Micromonospora
strains and representative species (Fig. 4). The biosynthetic
potential (number of BGCs detected by antiSMASH) of each
Micromonospora strain is reected in the color code. Of the 50
analyzed Micromonospora strains, 22 had between 7–13 BGCs
(blue), 12 strains had between 14–20 BGCs (green), 11 strains
had between 21–27 BGCs (yellow) and four strains showed even
more than 28 BGCs (red). This shows that Micromonospora has
a high potential for producing secondary metabolites.
For further analysis, a database of 87 genomes retrieved from
EzBioCloud was submitted to antiSMASH (for genomes also see
Fig. 4). Based on the antiSMASH results, we furthermore char-
acterized the distribution of BGCs from Micromonospora using
network analyses with BigScape.18 Overall, it was possible to
identify 2387 BGCs that could be grouped into 1033 BGC-
families (Table 1 and Fig. S1–S8†). Of these families, 773 were
singletons, meaning that they are only found in a single strain.
Thereby the majority of BGC-families belong to the type 1 pol-
yketide synthases (T1PKS) and the non-ribosomal peptide
synthetases (NRPS). To identify which of the Micromonospora
BGC families is already encoding a known compound, the
dataset from the MIBiG database was added to the network
analysis.19 Only 15 of 1033 BGCs belonged to or showed a high
similarity to the already known BGCs, most of which were pol-
yketides. This not only conrms that the genusMicromonospora
has a huge potential for producing secondary metabolites, but
also that there are potentially a lot of novel metabolites to
discover.20942 | RSC Adv., 2020, 10, 20939–209593. Micromonospora-derived natural
products
3.1. Macrolides
Macrolides are regarded as one of the most efficient natural
drug leads for treating immune and infectious diseases. They
consist of large macrocyclic lactone ring (14, 15, or 16-
membered) attached to one or more amino-deoxy sugars.
Biosynthetically, macrolides are polyketide-derived natural
products that utilize polyketide synthase (PKS) systems.20 Mac-
rolide antibiotics display a bacteriostatic action against a wide
range of pathogenic bacteria through binding to the 50S
subunit of the bacterial rRNA complex.21 Macrolides are char-
acteristic secondary metabolites for the genus Micromonospora
(Fig. 5–7), where several examples from this class of specialized
metabolites have been reported during the last y years.
3.1.1. Antimicrobial macrolides. Megalomicin was the rst
macrolide antibiotic reported from Micromonospora in 1969. It
was isolated from the soil-derived strain M. megalomicea as an
antibiotic mixture of several antimicrobial substances which
were identied as megalomicins A, B, C1, and C2 (1–4).22 In the
same year, the structure of megalomicin A was elucidated.23 In
1979, its structure was revised aer detailed X-ray crystallo-
graphic analysis.24 The biosynthesis of megalomicins resembles
that of erythromycin C (5) which is glycosylated to the amino-
deoxy sugar L-megosamine in the last step.25 Megalomicins
exert bacteriostatic activity primarily against Gram-positive
bacteria comparable to erythromycin (6) both in vitro and in
vivo.22 Moreover, megalomicin C1 (3) revealed a good antiviral
activity against swine fever virus and herpes simplex virus type 1
(HSV-1) by inhibiting the viral protein glycosylation.26 Later,
megalomicin A (1) was found to exhibit potent to moderate
antiparasitic activities (IC50 0.2, 1, 2, 3, and 8 mg mL
1) when
tested against Trypanosoma cruzi, Plasmodium falciparum, Try-
panosoma brucei, Leishmania donovani, and Leishmania major,
respectively. Megalomicin A (1) uniquely blocks vesicular
transport between the medial- and trans-Golgi, resulting in the
under-sialylation of the parasite proteins.27 Rosamicin (7),
another example of macrolide antibiotics isolated from M.
rosaria12 that is structurally more related to cirramycin A1 (8)
than erythromycin (6). Rosamicin (7) demonstrates broad
antibiotic activities, particularly against Gram-negative
bacteria. Besides, it has superior stability under acidic condi-
tions in comparison to megalomicins or erythromycins. The
rosamicin aglycone rosaramcin (9) along with its diacetate (10),
that exhibited the same antibiotic potency and spectrum as
rosamicin (7), were prepared via the asymmetric total synthesis
in 1986.28 One year later, during the screening for new antibi-
otics produced by actinomycetes collected at Izena Island,
Okinawa, Japan, three rosamicin analogues designated as ize-
namicins A3, B2, and B3 (11–13) were isolated from a soil-
derived Micromonospora strain. Only izenamicin B3 (12)
showed potent antibacterial effects against a panel of Gram-
positive and Gram-negative pathogenic bacteria.29 From a soil
strain M. chalea, a group of seven 16-membered macrolide
antibiotics structurally close to rosamicin (7) were reported asThis journal is © The Royal Society of Chemistry 2020
Fig. 4 Micromonospora phylogenetic tree generated with autoMLST. Color code is representing the number of BGCs identified by antiSMASH.
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View Article Onlinejuvenimicins A1–A4 (14–17) and juvenimicin B1–B3 (18–20).
They demonstrated antibacterial activity against Gram-positive
bacteria, particularly juvenimicin A3 (16) which was the mostThis journal is © The Royal Society of Chemistry 2020potent one (MIC 0.1–0.3 mg mL1).30 Ten years later, another
group of macrolide aglycones named rustmicin (21) and neo-
rustmicin A–D (22–25) with potent antifungal activity againstRSC Adv., 2020, 10, 20939–20959 | 20943
Table 1 Biosynthetic gene clusters and gene cluster families from 87
Micromonospora genomes
Cluster type BGCs Singletons Families Known (MIBiG)
PKSI 437 187 240 5
Others 328 119 158 2
Saccharides 47 10 18 1
Other PKS 280 56 79 5
PKS–NRP hybrids 174 71 92 0
NRPS 428 180 240 1
Terpene 403 40 68 1
RiPPs 290 110 138 0
Total 2387 773 1033 15
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View Article Onlinewheat stem rust fungus was obtained from the fermentation
broth of the same Micromonospora species.31–33 Later in 1998, it
was found that rustamicin (18) and its congeners mediate their
fungicidal activity via inhibition of the fungal inositol phos-
phoceramide synthase resulting in interrupted sphingolipid
biosynthesis.34 In 1980, further eighteen compounds called
mycinamicin I–XVIII (26–43) were added to the 16-membered
macrolide antibiotics family from a soil derived-M. griseorubida
strain. Interestingly, mycinamicins showed potent bacterio-
static activity against Gram-positive pathogenic bacteria (MIC
0.1–3.12 mg mL1).35,36 Aer eight years, both mycinamicin IV
(29) and VII (32) were synthesized.37 Later, a biosynthetic
pathway for this class of macrolides was proposed depending
on the several biosynthetic intermediates that were isolated,
particularly mycinonic acid (44), in addition to many of
bioconversion studies.38 In 2003, their biosynthetic gene cluster
was completely determined in M. griseorubida suggesting that
some genes in the cluster might have been horizontally trans-
ferred from Streptomyces spp.39 The large non-polyene macro-
lide perimycin (45) was rst isolated from Streptomyces primycini
and showed potent antibiotic activity towards Gram-positive
bacteria.40 Later, it was obtained in a higher quantity from M.
galareinsis.41 Perimycin (45) has a unique macrolide scaffold
with attached guanidine and arabinose moieties that enables it
to target the bacterial cell membrane and alter its perme-
ability.42 In 2014, this interesting antibiotic was re-evaluated
against prevalent multi-resistant Gram-positive bacteria
responsible for common skin infections.43 Besides its prom-
ising antibiotic activities, perimycin (45) possesses signicant
antifungal effects against a wide range of pathogenic fungi.44 Its
complex formation with the fungal cell membrane ergosterol is
considered the primary mode of action responsible for its
antifungal properties.45 All Micromonospora-derived antimicro-
bial macrolides are depicted in Fig. 5.
3.1.2. Anticancer macrolides. Besides their signicant
antimicrobial activities, macrolides derived from Micro-
monospora have demonstrated considerable in vitro anti-
proliferative effects towards various human cancer cell lines.
The rst anticancer macrolide recovered from Micromonospora
was in 1993, when the 60-membered polyene macrolides qui-
nolidomicins A1, A2 and B1 (46–48) were isolated and charac-
terized from a soil-derived M. chalcea.46 Both quinolidomicins20944 | RSC Adv., 2020, 10, 20939–20959A1 and B1 (46, 48) demonstrated signicantly potent in vitro
antiproliferative activity (IC50 25–327 ng mL
1) toward an array
of human cancer cell lines including multidrug-resistant cells.46
Quinolidomicins are considered the largest macrolide of
terrestrial origin identied to date. Recently, their biosynthetic
gene cluster was characterized via heterologous expression to be
over 200 kb (154 domains in 34 modules). Detailed chemical
characterization of the product led to a structural revision, in
which the hydroxy group in the quinone moiety of quinolido-
micin A1 (46) was replaced by an amino group (49).47 In 2011,
while exploring the diversity of actinomycetes in the deep-
Mediterranean seaoor, a new Micromonospora strain was
found to produce two new 20-membered macrolides, levantilide
A and B (50, 51).48 Two years later, levantilide C (52) was isolated
from another Micromonospora strain that was isolated from
shallow coastal waters near the island of Chiloe, Chile.49 All
reported levantilides showed signicant in vitro anti-
proliferative activity against different human cancer cell lines
(2.6–8.3 mg mL1).48,49 In 2018, utilizing bioinformatic
approaches together with spectroscopic tools led to the isola-
tion and full characterization of neaumycin B (53), a complex
polycyclic macrolide with 19 stereo centers from a marine-
derived Micromonospora strain. Structural characterization of
such complex compounds requires selective degradation, crys-
tallization, derivatization, X-ray diffraction analysis, total
asymmetric synthesis, or other time-consuming methods to
assign the complete stereo-structure. Alternatively, the genome
of the producing microbe was sequenced to identify the gene
cluster of neaumycin (neu). By integrating the known stereo-
specic biosynthetic enzymes with comprehensive NMR anal-
ysis, the full stereo-structure of neaumycin B (53) was
characterized. This unique metabolite revealed potent and
selective in vitro inhibitory activity against glioblastoma cell line
indicating it as a promising drug candidate.50 All anticancer
Micromonospora-derived macrolides are depicted in Fig. 6.
3.1.3. Macrolides with other biological activities. In 1996,
bio-guided chemical investigation of a soil-derived Micro-
monospora strain led to the isolation of ve novel ascomycin-like
macrolides, antascomicins A–E (54–58). They were found to
bind strongly to the rapamycin-binding protein FKBP12 (IC50
0.7 ng mL1) and antagonize the immunosuppressive activity of
rapamycin.51 These interesting effects of antascomicins family
prompted a group of organic chemists in 2005 to initiate an
antascomicins total synthesis campaign as potential ligands for
FKBP12 protein that could promote the growth of damaged
nerves in the peripheral nervous system without immunosup-
pressive side effects. They managed to totally synthesize
antascomicin B (55) in 52 steps from commercially available
starting materials.52 Later, another group reported the total
asymmetric synthesis of the C1–C21 and C22–C34 fragments of
antascomicin A (54).53,54 Searching for natural cholesterol-
lowering drug leads, the ethyl acetate extract of a soil-derived
Micromonospora strain displayed signicant activity as an acti-
vator of the LDL-receptor gene promoter. LDL-receptor (LDL-R)
mediates LDL cellular uptake and hence, reducing serum
cholesterol level. Bio-guided fractionation of this extract led to
the isolation of the selective LDL-R promoter activator, SCHThis journal is © The Royal Society of Chemistry 2020
Fig. 5 Macrolides derived from Micromonospora with antimicrobial activities (compounds 1–45).
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View Article Online351448 (59).55 Later, several efforts for the enantioselective
synthesis of this promising molecule were reported.56–58 In the
course of the search for new inhibitors of starsh (AsterinaThis journal is © The Royal Society of Chemistry 2020pectinifera) embryonic development, three new balomycin-type
16-membered macrolides micromonospolides A–C (60–62) were
isolated from the fermentation broth of a marine-derivedRSC Adv., 2020, 10, 20939–20959 | 20945
Fig. 6 Macrolides derived from Micromonospora with anticancer activity (46–53), and other miscellaneous macrolides (compounds 54–62).
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View Article OnlineMicromonospora strain. They were able to inhibit gastrulation of
starsh embryos at MIC of 0.01, 0.011, and 1.6 mg mL1,
respectively.59 Miscellaneous macrolides (54–62) are depicted in
Fig. 6.
3.1.4. Unusual macrolides: spirotetronates. Spi-
rotetronates are a unique family of complicated macrolide that
features tetronic acid (spiro-linked to a cyclohexene ring) linked
to a trans-decalin moiety. The structure is usually connected to
two sugar moieties, of which one is a nitro sugar, D-tetronitrose,
and the other one is a chain of deoxy sugars, L-digitoxoses and L-
amicetoses. In terms of biological effects, this class of
compounds exhibits wide-range of biological activities,
including antitumor, antibacterial and antiviral activities.
Tetrocarcins A–C (63–65) were the rst representatives of spi-
rotetronates in 1980 and obtained in a high yield from M.
chalcea.60 Later, tetrocarcins E and F (66, 67) were reported from
the same strain.61 All the reported tetrocarcins demonstrated
signicant antibacterial effect against Gram-positive bacteria
(MIC 0.1–30 mg mL1), and potent in vivo antitumor effects
against different human breast cancer.60,61 In 2018, tetrocarcins20946 | RSC Adv., 2020, 10, 20939–20959AC6H, N, H and Q (68–71) were isolated from the marine-
derived strain M. carbonacea.62 In 1991, a group of Japanese
chemists has achieved the rst total synthesis of tetrocarcins
aglycone (72, 73) via coupling of spirotetronate with octahy-
dronaphthalene aldehyde.63 Tetrocarcins mediate their anti-
bacterial activity through the inhibition of bacterial DNA
dependent RNA polymerase, and this activity is decreased with
the decrease in the number of deoxy sugars attached to the
aglycone.64 Moreover, they mediate their anticancer effect
through induction of apoptosis in cancer cells by inactivation of
phosphatidylinositide-30-kinase-dependent pathway.65 In 2000,
another example of spirotetronates, with an iso-butanoyl dig-
itoxose unit instead of the acetyl digitoxose, arisostatins A and B
(74, 75) that were isolated from a halophilic Micromonospora
strain. Both metabolites demonstrated biological activity like
their parent spirotetronates, tetrocarcins.66 Recently, a marine-
derived strain M. harpali was found to produce a group of new
spirotetronates analogs (76–84) that displayed strong to
moderate antibacterial activities against Gram-positive bacteria
(MIC 0.016–8 mg mL1).67This journal is © The Royal Society of Chemistry 2020
Fig. 7 Unusual macrolides derived from Micromonospora (compounds 63–84).
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View Article Online3.2. N-containing metabolites
3.2.1. Aminoglycoside antibiotics. Aminoglycosides are
one of the oldest classes of antimicrobial agents. They were
mainly reported from either soil-derived Streptomyces or
Micromonospora species (Fig. 8).68 Generally, the aminoglyco-
side molecule consists of two or more amino sugars connected
to an aminocyclitol nucleus. They have broad-spectrum anti-
bacterial activity against Gram-positive and Gram-negative
bacteria, mycobacteria, and protozoa.69 Their mode of actionThis journal is © The Royal Society of Chemistry 2020is mediated by binding to the aminoacyl site (A-site) of the
bacterial 16S ribosomal RNA (rRNA), where they interrupt the
“proof-reading” process that ensures the accuracy of protein
synthesis, in addition to the 50S ribosomal subunit, which
inhibits the translocation and ribosome recycling.70,71 Investi-
gation of the biosynthetic origins and pathways for this vital
class of antibiotics has remarkably developed during the past
decade. Biosynthetic gene clusters of different aminoglycoside
derivatives including gentamicin have been identied to date.
The excellent review of Kudo and Eguchi summarized the latestRSC Adv., 2020, 10, 20939–20959 | 20947
Fig. 8 Aminoglycoside antibiotics derived from Micromonospora (compounds 85–112).
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View Article Onlineadvances in the characterization of aminoglycosides biosyn-
thetic genes.72
Gentamicin complex was the rst reported aminoglycoside
from Micromonospora in 1963.73 This 4,6-disubstituted20948 | RSC Adv., 2020, 10, 20939–20959aminocyclitol antibiotic complex is mainly composed of three
major components; gentamicin C1, C1a and C2, and were iso-
lated from two strains: M. echinospora NRRL 2953 and M. echi-
nospora NRRL 2985 from a soil sample in New York, USA. TheThis journal is © The Royal Society of Chemistry 2020
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View Article OnlineC1, C1a and C2 (85–87) components are composed of a central
2-deoxystreptamine (di-aminocyclitol) 4,6-disubstituted with
the secondary sugars garosamine and purpurosamine. On the
other hand, different trace components, such as gentamicins A,
A1, A2, A3, A4, B, B1 (88–94) were found to be produced by
several gentamicin producing Micromonospora strains. Genta-
micins have shown potent antibacterial effect against a panel of
Gram-positive and Gram-negative pathogenic bacteria both in
vitro (MIC 0.1–10 mg mL1) and in vivo. In addition, they
exhibited excellent pharmacokinetic properties and moderate
tolerability within their therapeutic dose. So, they were
successfully introduced into the pharmaceutical market in 1971
and from this time, they were used for diverse medical appli-
cations. Gentamicins successful story has encouraged further
aminoglycosides exploration from Micromonospora.74 In 1974,
Sisomicin (95), an aminoglycoside antibiotic that differs from
gentamicins by having unsaturated sugar ring, was isolatedFig. 9 Other N-containing metabolites derived fromMicromonospora. C
132–138 are alkaloids with antimicrobial activity, compounds 139–145 a
with antimicrobial activity.
This journal is © The Royal Society of Chemistry 2020from M. inyoensis NRRL 3292. This antibiotic, in contrast to
gentamicin, is produced substantially as a single component
and showed interesting antibacterial effect against both Gram-
positive and negative bacteria with MIC values ranged from
0.01–7.5 mg mL1.75 It displayed better antibacterial effect
compared to other structurally-related aminoglycoside mole-
cules such as gentamicin, tobramycin, and amikacin, which
could be related to the minor difference found in the ring I of
sisomicin (95).76 Sisomicin (95) has also shown to be an
attractive molecule to design and modify semisynthetic ami-
noglycoside analogues not only due to its potent antibacterial
activity but also its resistance to numerous aminoglycoside-
modifying enzymes, such as aminoglycoside phospho-
transferases (APHs) and aminoglycosides nucleotidyl-
transferases (ANTs), by lacking the 30- and 40-OH groups in ring
I.77 Mutamycin (96), a sisomicin (95) analogue, was found to be
produced upon addition of 2-deoxystreptamine to theompounds 113–131 are alkaloids with anticancer activity, compounds
re peptides with anticancer activity, compounds 146–148 are peptides
RSC Adv., 2020, 10, 20939–20959 | 20949
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View Article Onlinefermentation broth of M. inyoensis. It has shown antibacterial
activity similar to sisomicin (95) (MIC 0.08–3 mg mL1).78
Additionally, sagamicin (97) was isolated from the fermentation
broth of M. sagamiensis MK 62, and demonstrated antibacterial
activity against Gram-positive and negative bacteria similar to
gentamicin C1 (85) with MIC values of 0.01–8.3 mg mL1.79
Sagamicin (97) was considered one of the most effective agents
against Enterobacteriaceae (MIC 2 mg mL1) and displayed
higher antipseudomonal activity than that of gentamicins.80 A
year aer, verdamicin (98) along with its 1-N-ethyl derivative,
vertilmicin (99) were isolated from both M. grisea and M. oli-
voasterospora, respectively, with antibacterial activity against
Gram-positive and Gram-negative bacteria (MIC 0.03–3.0 mg
mL1) similar to that of sisomicin (95) and gentamicin C1
(85).81,82 In 1977, fortimicins A–C (100–102) were produced as
a mixture of several biologically active components from M.
olivoasterospora as usually the case with aminoglycoside anti-
biotic fermentations.83 Fortimicin A (100) exhibited broad-
spectrum potent antibacterial effects against Gram-positive
and negative bacteria both in vitro (MIC 0.02–10 mg mL1) and
in vivo, while fortimicin B and C (101, 102) were less active.84
From the same Micromonospora strain, antibiotic SF-1854 was
isolated as a byproduct and characterized as 1, N-for-
mylfortimicin A (103). It showed 8–16 times weaker activity than
fortimicin A (100). However, its activity against Salmonella,
Pseudomonas and Streptococcus faecalis was relatively close to
fortimicin A (100) with MIC values ranged from 6.25–50 mg
ml1.85 Later, further fortimicins C, D and K (104–106) were
isolated from the same strain. Fortimicins C and D (104, 105)
showedmore potent antibacterial activity against Gram-positive
and negative bacteria than fortimicin A (100) with MIC values of
0.02–0.33 mg mL1.86 In the same year, antibiotic G-418 (107)
and antibiotic JI-20A (108) were isolated from M. rhodorangea
NRRL 5326 and M. purpurea JI-20, respectively. They exhibited
broad-spectrum antibacterial activity with MIC values of 16–64
mg mL1. Moreover, they showed signicant activity against
protozoa, amoebae, tapeworm, and pinworm infections in
mice.87 M. zionensis was found to produce a broad-spectrum
aminoglycoside antibiotic named G-52 (109) with potent
activity against both Gram-positive and negative bacteria with
MIC values ranged from 0.01–17.5 mg mL1.88,89 Furthermore,
antlermicin A–C (110–112), were isolated from the culture of M.
chalcea. They showed strong antibacterial activity against
Bacillus subtilis with MIC values of 0.015, 0.05, 0.039 mg mL1,
respectively. In contrast to the other aminoglycosides, they did
not exhibit any activity against Gram-negative bacteria.
However, they inhibited the growth of sarcoma cells in vitrowith
IC50 values of 1, 1.56, 12.5 mg mL
1, respectively.90,91 All Micro-
monospora-derived aminoglycosides are depicted in Fig. 8.
3.2.2. Anticancer alkaloids. Alkaloids are class of naturally
occurring nitrogenous organic compounds. They are produced
by a large variety of terrestrial and marine organisms as well as
microorganisms including actinomycetes. Most alkaloids
derived fromMicromonospora species (Fig. 9) showed promising
anticancer and antimicrobial activities. In 1988, Yang et al. re-
ported the rst alkaloid from the genus Micromonospora.
During their chemical investigation of the soil-derived strainM.20950 | RSC Adv., 2020, 10, 20939–20959neihuensis, they have isolated a piperazine-type alkaloid, nei-
humicin (113) which demonstrated potent in vitro anti-
proliferative effect toward KB cell line (IC50 0.94 mg mL
1).92
Later, they papered a group of semi-synthetic analogues (114–
117) to study their structure–activity relationship which indi-
cated that the presence of an alkyl ether group together with the
substitution at the two benzene rings are essential for the
cytotoxic effect of these molecules (IC50 0.08–0.94 mg mL
1).93 A
new member of the anthramycin antibiotics family, sibanomi-
cin (118) was identied from the culture ltrate of a marine-
derived Micromonospora strain. Sibanomicin (118) showed
signicant in vivo antitumor activity in mice bearing leukemia
P388 cells.94 In 2000, bioprospecting of the marine sponge-
associated actinomycetes led to the identication of staur-
osporine (119)-producing Micromonospora strain. Large scale
fermentation of this new strain afforded further two indolo-
carbazole derivatives, 40-N-methyl-50-hydroxystaurosporine
(120) and 50-hydroxystaurosporine (121). The isolated alkaloids
showed potent in vitro antiproliferative activity against a panel
of human cancer cell lines (IC50 0.001–0.04 mg mL
1) as a result
of inhibition of the protein kinase C (IC50 44 ng mL
1).95 Later,
staurosporine (119) has shown to induce apoptosis in various
cancer lines by activating caspase-3.96 Recently, staurosporine
(119) along with its congeners are considered non-selective
kinase inhibitors, and this lack of specicity has precluded
their clinical use, however, they became important compounds
to be used frequently for various biochemical experiments.97
Early 1990s, a number of synthetic approaches for staur-
osporine (119) and its aglycone (122) were described in different
reports.98–100 The biosynthesis of staurosporine (119) and its
analogues was proposed to start with the amino acid L-trypto-
phan which in turn converted to an imine by the oxidase
enzyme StaO. Subsequently, two imine groups are dimerized to
afford chromopyrrolic acid (123). Finally, an aryl–aryl coupling
followed by decarboxylation reaction proposed to be catalyzed
by a cytochrome P450 enzyme leads to the formation of staur-
osporine aglycone (122).101 In 2002, staurosporine (119)
biosynthetic gene cluster was cloned and successfully expressed
in Streptomyces lividans.102 The aminoquinone alkaloid strep-
tonigrin (124) was originally isolated from Streptomyces occulus
in 1963, and again in 2002 when Wang and his co-workers re-
ported a soil-derived Micromonospora strain that produced
streptonigrin (124) in large quantities along with its oxopropyl
analogue (125). Aerward, several synthetic chemists have
developed different methods for the total synthesis of this
unique alkaloid (124).103–105 Moreover, the piperidine alkaloids,
albonoursin (126) and its N-methyl derivative (127) together
with the siderophore norcardamine (128) were also recovered
from the sameMicromonospora strain fermentation broth. Both
streptonigrin (124) and its analogue (125) were able to induce
apoptosis in the human neuroblastoma SH-SY5Y cells through
p53-dependent mechanism.106 Recently, its biosynthetic gene
cluster (48 genes) was fully characterized proposing a novel
enzymatic reactions pathway where lavendamycin methyl ester
(129) is formed and subsequently an aromatic dioxygenase
StnB1/B2 system catalyzes a regiospecic cleavage of the N–C80
bond of the lavendamycin methyl ester (129) indole ring.107 InThis journal is © The Royal Society of Chemistry 2020
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View Article Online2018, the bioactivity-guided chemical proling of the Micro-
monospora strain recovered from the East China Sea sediment
led to the isolation of a new 26-membered polyene macrolactam
compound FW05328-1 (130), in addition to a known pyridine-
derived polyene, aurodox (131). Both metabolites exhibited
considerable in vitro antiproliferative activities against
a number of human tumor cell lines with IC50 range 0.002–30.7
mg mL1.108Fig. 10 Quinones derived fromMicromonospora. Compounds 149–164
activity.
This journal is © The Royal Society of Chemistry 20203.2.3. Antimicrobial alkaloids. Similarly, several antimi-
crobial alkaloids with diverse chemical structures were reported
from different species of the genus Micromonospora. In 2004,
three diketopiperazine alkaloids (Sch 725418, fellutanine, and
indolmycin) (132–134) with moderate antibacterial and anti-
fungal properties were isolated from a new Micromonospora
strain.109 In the same year, a novel dibenzodiazepine alkaloid,
diazepinomicin (135), was isolated from a marine-derivedhave antimicrobial activities, and compounds 165–176 have anticancer
RSC Adv., 2020, 10, 20939–20959 | 20951
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View Article OnlineMicromonospora species. Diazepinomicin (135) represents
a unique class comprising a rare dibenzodiazepine core
conjugated to a farnesyl side chain. It exhibited modest anti-
microbial activity against many pathogenic Gram-positive
bacteria with MICs of about 32 mg mL1.110 Besides, dia-
zepinomicin (135) demonstrated broad in vitro antiproliferative
activity against a panel of cancer cell lines and in vivo efficacy in
xenogra tumor models.111 Preclinical data suggested that dia-
zepinomicin (135) is a promising anticancer agent with a dual-
mode of action; selective binding to the peripheral benzodiaz-
epine receptors and inhibition of the Ras–MAPK pathway.112
Furthermore, characterization of its biosynthetic gene cluster
highlighted the enzymatic complexity needed to produce such
structural type which is unprecedented among microbial
metabolites.113 Recently, some diketopiperazines (136–138) with
weak antibacterial activity (128 mg mL1) were recovered from
a sponge-associated Micromonospora strain. All Micro-
monospora-derived alkaloids are depicted in Fig. 9.
3.2.4. Anticancer peptides. Peptides are short chains of
amino acid monomers linked through peptide bonds, which
formed once the carboxyl group of an amino acid reacts with the
amino group of another one. Peptides are classied according
to their biosynthetic origin to ribosomal and non-ribosomal
peptides. Ribosomal peptides in higher organisms are the
products of a cellular ribosome, and functioning as hormones
and signaling molecules. Some microorganisms produce ribo-
somal peptides as antibiotics.114 On the other hand, non-
ribosomal peptides are assembled by enzymes complexes.
They are common in unicellular organisms, fungi and bacteria
and biosynthesized through non-ribosomal peptide synthetases
complex. These complexes contain many different modules to
perform diverse chemical manipulations on developing the
product. These peptides are oen cyclic and can have highly
complex structures.115 In the past twenty years, there were
a number of reports on bioactive peptides produced by different
strains of Micromonospora (Fig. 10). The very rst of this group
was discovered in 1995 when the lipopeptides rakicidins A and
B (139, 140) were discovered from a soil-derivedMicromonospora
strain. Both lipo-tripeptides are cyclized through a b-hydroxy
fatty acid and exhibited potent in vitro antiproliferative activity
against M109 cell line (IC50 55, 230 ng mL
1). Rakicidin B (140)
differs from A (139) by one methylene group in the lipid side
chain, indicating that the length of the lipid side chain may
signicantly affect the cytotoxic activity of this class of
compounds.116 Later, a screening study on microbial natural
products revealed that rakicidin A (139) triggers novel hypoxia-
selective cell death in solid tumors through caspase-dependent
and independent pathways.117,118 The absolute conguration of
rakicidin A (139) was assigned through its total synthesis in
2014.119 Then, a structure–activity relationship study indicated
that both the conjugated diene moiety together with the long
alkyl chain are essential features for the unique cytotoxic
activity of rakicidin A (139).120 Recently in 2018, further rakici-
din analogues (E and G–I) (141–144) were recovered from the
marine M. chalcea FIM 02-523.121 In 1997, a novel bioactive
depsipeptide, thiocoraline (145), was characterized from the
culture broth of a marine Micromonospora strain. This unique20952 | RSC Adv., 2020, 10, 20939–20959compound showed exceptional cytotoxicity against a panel of
cancer cell lines (IC50 0.002 mg mL
1) and strong antibacterial
activity against Gram-positive bacteria (MIC 0.03 mg mL1).122
Recently, thiocoraline (145) biosynthetic gene cluster was
successfully characterized and expressed in two Streptomyces
strains.123 Aer its challenging total synthesis, thiocoraline
(145) was found to induce cell death by binding to DNA which
led to cell necrosis.124 Peptides derived from Micromonospora
are depicted in Fig. 9.
3.2.5. Antibacterial peptides. Many antibacterial peptides
were reported from differentMicromonospora species (Fig. 10) in
the past thirty years. In 1980, during an antibiotics screening
program, a novel dipeptide, N-(2,6-diamino-6-hydrox-
ymethylpimelyl)-L-alanine (146) was obtained from the culture
broth of the marine-derived M. chalcea. This metabolite was
able to inhibit the in vitro growth of E. coli by interference with
the bacterial cell wall biosynthesis.125 Ten years later, an
unusual sulfur-rich antibiotic, Sch 40832 (147) was isolated
from the soil inhabitant strain M. carbonacea.126 Later, another
unique dipeptide, SB-219383 (148) with selective and potent
inhibitory activity towards the bacterial tyrosyl tRNA synthetase
was isolated from a Micromonospora strain recovered from
marine-sediment.1273.3. Quinones
The quinones are a class of aromatic organic molecules derived
from different aromatic nuclei such as benzene or naphthalene
by the conversion of an even number of double bonds into
ketone groups leading to a fully conjugated cyclic dione struc-
ture.Micromonospora species have proven to be a crucial source
of medicinally important quinones (Fig. 11) in the last thirty
years, in particular, the 9,10-anthraquinone class. Most of the
Micromonospora-derived anthraquinones have found to be
effective treatments for different types of malignant tumors and
bacterial infections.128 Biosynthetically, these quinones origi-
nate from the polyketide pathway,128 and act on several bio-
logical targets including, DNA, topoisomerase II enzyme, and
bacterial cell wall. Also, they can undergo intracellular redox
reactions to generate excessive reactive oxygen species (ROS)
that induces direct cell death. A number of Micromonospora-
derived anthraquinones have reached the drug market,
however, their adverse effects, particularly, cardiotoxicity,
limited their use.129
3.3.1. Antimicrobial quinones. In 1986, crisamicin A (149),
derived from the halotolerant M. purpureochromogenes, was the
rst anthraquinone antibiotic reported. This iso-
chromanequinone new member was active against a panel of
Gram-positive pathogenic bacteria withMIC values ranged from
0.2–1 mg mL1.130 Two years later, crisamicin C (150), the
epoxide analogue of crisamicin A (149) was discovered from the
same species and exhibited stronger antibacterial activity
against Gram-positive bacteria (MIC 0.125–0.52 mg mL1).131 In
the same year, the biosynthesis of this class of compounds via
the polyketide pathway was elucidated.128 Later in 2008,
synthetic efforts resulted in the total asymmetric synthesis of
crisamicin A (149).132,133 Dynemicin A (151), which was rstThis journal is © The Royal Society of Chemistry 2020
Fig. 11 Ansamycins antibiotics derived from Micromonospora (compounds 177–200).
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View Article Onlineisolated from the soil-derived M. chersina, featuring a unique
hybrid of anthraquinone and an l,5-diyn-3-ene system, was
found to have an extraordinary growth inhibitory effect against
both Gram-positive (MIC 13–63 pg mL1) and Gram-negative
(MIC 63 mg mL1) bacteria. Besides, its triacetate derivative
(152) showed excellent in vivo therapeutic effect with consider-
able tolerability.134 Shortly aer dynemicin A (151) discovery,
another deoxy analogue (153) was isolated fromM. globosa with
similar antibacterial spectrum.135 Besides their outstanding
antibiotic properties, dynemicins also demonstrated potent in
vitro and in vivo anticancer effects against several human cancer
cell lines (IC50 0.1–1 mg mL
1).134 Dynemicins' primary mode of
action is to intercalate into the minor groove of the DNA double
helix by their enediyne moiety. Subsequently, chemically-
induced conformational changes resulting in an irreversible
double-stranded cleavage and immediate cell death. This
mechanism is extremely cytotoxic due to the lack of anyThis journal is © The Royal Society of Chemistry 2020appropriate mechanism to repair a double-stranded cleavage of
DNA in both prokaryotic and eukaryotic cells,136 and hence this
prevents their further development as a drug. However, another
Streptomyces-derived antibiotic known as neocarzinostatin (154)
have the same enediyne functionality of dynemicins and act by
the same mechanism, was approved for clinical use.137 The
biosynthesis of dynemicin A (151) was proposed by connecting
two heptaketide chains derived from seven head-to-tail joined
acetate units.138 Later, a number of dynemicins (L–Q) (155–160)
were further isolated from the dynemicin A producing organism
M. chersina. They revealed much weaker antibacterial activity
(MIC 0.08–1.25 mg mL1) than their parent compound dyne-
micin A (151) due to the loss of the essential enediyne
moiety.139,140 Spartanamicins A and B (161, 162), two antifungal
antibiotics, were reported from a Micromonospora strain iso-
lated from the medicinal plant Asparagus officinalis. Both
anthracycline antibiotics have demonstrated potent antifungalRSC Adv., 2020, 10, 20939–20959 | 20953
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View Article Onlineactivity (MIC 0.2–1 mg mL1) against a wide range of pathogenic
fungi.141 Besides, spartamicin B (162) has shown a promising in
vivo activity against several multi-resistant fungal strains with
no toxicity at the therapeutic dose (10 mg).142 In 2004, a marine-
derived Micromonospora strain was found to produce a novel
antimicrobial anthracycline, micromonomycin (163). This
metabolite exhibited antibacterial activity against both Gram-
positive and Gram-negative bacteria with MIC values range
0.5–4 mg mL1. Additionally, it showed moderate antifungal
properties with MIC values of 30–35 mg ml1.143 Recently,
a potent antiplasmodial polycyclic anthraquinone namedMDN-
0185 (164) was isolated from a soil-derived Micromonospora
species. It was able to inhibit the growth of the multidrug-
resistant Plasmodium falciparum with IC50 of 9 ng mL
1.144
3.3.2. Anticancer quinones. In 1980, a number of dauno-
rubicin derivatives (165–168) with potent in vivo antileukemic
activity were recovered from an extremophilic Micromonospora
strain.145 Later, a unique antitumor nitroanthracycline analog,
cororubicin (169) derived from amarineMicromonospora strain,
was able to inhibit the growth of many cancer cell lines (IC50
0.8–4 mg mL1) by generating intracellular active superoxide
radicals.146 From the endophytic strain M. lupini, two new
anthraquinones lupinacidins A and B (170, 171) were isolated.
Both metabolites were found to effectively inhibit the invasion
of murine colon 26-L5 carcinoma cells.147 Four years later,
lupinacidin C (172) was isolated from the sameMicromonospora
strain and prepared by total synthesis. Additionally, it demon-
strated the most potent inhibitory effects among the congeners
on the invasion of colon cancer cells, indicating that the length
of the alkyl side chain is essential for the anti-invasive activity.148Fig. 12 (A) Natural products isolated from genus Micromonospora acc
derived from Micromonospora genus, (C) secondary metabolites classes
20954 | RSC Adv., 2020, 10, 20939–20959Recently, a tunicate associated Micromonospora strain, was
found to produce some novel anthracyclinones (173–176) with
moderate in vitro antiproliferative effects on the colon adeno-
carcinoma cells (IC50 6–13 mg mL
1).149 All quinone-derived
compounds that have been reported from Micromonospora are
depicted in Fig. 10.3.4. Ansamycins
Ansamycins are a group of antibiotics with basket-like mole-
cules that comprise an aromatic moiety (naphthalene or
naphthoquinone ring) bridged at non-adjacent locations by an
aliphatic chain. Their carbon skeleton is derived from the pol-
yketide pathway via a polyketide synthase using an unusual
starter unit.150 Rifamycin (177) was the rst example in this class
of antibiotics which was rst isolated from Streptomyces medi-
terranei by Sensi and co-workers in 1959.151 Ansamycins show
a broad spectrum of antibiotic activity against Gram-positive,
particularly Mycobacteria, but to a lesser extent, Gram-negative
bacteria. The antibacterial activity of ansamycins results from
their ability to selectively inhibit the bacterial DNA-dependent
RNA polymerase. There are several ansamycin related antibi-
otics reached the market e.g. rifampicin (178) and geldanamy-
cin (179). During the last thirty years, several ansamycin
antibiotics were reported from different Micromonospora
species (Fig. 12), particularly the marine ones.
3.4.1. Antibacterial ansamycins.Halomicins A–D (180–183)
were the rst example of Micromonospora-derived ansamycins.
They were isolated from the marine strain M. halophytica and
demonstrated potent antibacterial action against a wide rangeording to the year of publication, (B) bioactivities of natural products
derived from Micromonospora genus.
This journal is © The Royal Society of Chemistry 2020
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View Article Onlineof Gram-positive bacteria (MIC 0.1–1 mg mL1).152 In 2009,
rifamycin S along with its geometric isomer (184, 185) were
produced from M. rifamycinica, a marine sediment-derived new
strain. They exhibited potent in vitro antibacterial activity
against a panel of pathogenic Gram-positive bacteria including
methicillin-resistant Staphylococcus aureus (MRSA) (MIC 0.03–
0.25 mg mL1).153 In 2017, a group of novel amino ansamycins,
named sporalactams A–F (186–191) were isolated from another
marine sediment-derived Micromonospora strain, and demon-
strated very potent in vitro antibacterial effects against both
Gram-positive and Gram-negative pathogenic bacteria
including Mycobacterium tuberculosis (MIC 0.0008–0.06 mg
mL1).154 One year later, the activation of the positive regulator
gene mas13 induced the expression of the cryptic gene cluster
mas, which was responsible for the biosynthesis of nine unusual
pentaketide ansamycins, namely, microansamycins A–I (192–
200) in a marine inhabitant Micromonospora species.155
4. Conclusions
Natural products derived from the genus Micromonospora
possess a unique chemical diversity with huge therapeutic
values making it an untapped resource of drugs and drug leads.
Since its discovery almost 100 years ago, this genus has become
a vigorous model for the discovery of naturally-derived drug
leads. The collection of thousands of Micromonospora strains
(Fig. 1) globally together with almost y years of research effort
in both academia and industry has generated a resource that
enabled to compare the biosynthesis of natural products among
closely related environmental strains. This comparison has also
revealed complications associated with microbial gene devel-
opment and will continue to provide insights into the mecha-
nisms of generating new structural diversity. Extensive
biochemical investigation ofMicromonospora has conrmed the
concept that new microbial taxa that inhabit un- or under-
explored environments such as marine habitats represent
a promising source for natural product discovery. In general,
the main source for the recovery and isolation of Micro-
monospora strains is soil (Fig. 2). Also, they were found as
endophytic microorganisms associated with plant tissues. In
marine ecosystems, they were isolated mainly from sediments,
and marine organisms such as ascidians, sponges and so
corals. Additionally, there were few examples of talented
Micromonospora species that inhabiting extreme environments
(Fig. 2). Until 1980, soil-derived Micromonospora species were
considered the main source of their specialized metabolites.
Aerward, the interest in marine-derived species was
increasing, and became a crucial source of chemical diversity
especially in the last eight years (Fig. 12A). Most of the
compounds identied from only 34% of the species reported in
this genus (30 from 88 reported species). Additionally, its
genomic analysis revealed a lot of unknown BGCs indicating
their unprecedented potential for novel chemical leads
discovery. Most of the Micromonospora-derived metabolites
have shown excellent antimicrobial and anticancer effects
(Fig. 12B), in particular, those belong to the macrolides, ami-
noglycosides, and ansamycins class of compounds (Fig. 12C).This journal is © The Royal Society of Chemistry 2020There are likely two major approaches to drug discovery from
Micromonospora and other actinobacteria. The rst and most
common is cultivation dependent, in which isolated species are
fermented, and subsequently, the produced secondary metab-
olites are recovered. Special requirements are needed not only
for growth, but also for secondary metabolites the production
makes this approach involves extensive effort. Besides, this
cultivation-dependent technique is unable to unlock the full
biosynthetic potential of such microorganism. The second
approach is the genome-dependent bioprospecting in addition
to chemoinformatic tools that can detect the silent biosynthetic
gene clusters in the Micromonospora. Subsequent activation or
heterologous expression of such gene clusters would potentially
lead to the creation of robust pipelines for drug discovery from
this genus. In conclusion, the continuous need for new bioac-
tive molecules is of substantial importance. Micromonospora
species provide a worthy platform for the discovery of novel
biologically active compounds. More than 100 molecules have
been reported from terrestrial strains including plant-
associated ones. However, the less explored marine species
along with those derived from extreme habitats afforded only 87
compounds, indicating a great potential for the discovery of
novel therapeutic lead scaffolds upon the continuous investi-
gation of Micromonospora from underexplored habitats in the
future.
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N. Moss, H. W. Nützmann, G. Pan, A. Pati, D. Petras,
F. J. Reen, F. Rosconi, Z. Rui, Z. Tian, N. J. Tobias,
Y. Tsunematsu, P. Wiemann, E. Wyckoff, X. Yan, G. Yim,
F. Yu, Y. Xie, B. Aigle, A. K. Apel, C. J. Balibar,
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